EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

Naveen Kumar Velayutham, Tamilanban Thamaraikani, Shadma Wahab, Mohammad Khalid, Gobinath Ramachawolran, Shahabe Saquib Abullais, Ling Shing Wong, Mahendran Sekar, Siew Hua Gan, Angel Jemima Ebenezer, Mrinalini Ravikumar, Vetriselvan Subramaniyan und 3 weitere

Frontiers in Pharmacology · 28.03.2023 · 14

DOI: 10.3389/fphar.2023.1150270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.03.2023. Verfasst von Naveen Kumar Velayutham und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) signals cell survival, cell migration, osteogenesis, cell proliferation, angiogenesis, and vascular permeability by binding to VEGF receptor 2 (VEGFR-2). Osteosarcoma is the most common primary bone cancer, majorly affects young adults. Activation of VEGFR-2 signaling is a therapeutic target for osteosarcoma. The present study aimed to evaluate the potency of stylopine in regulation of the VEGFR-2 signaling pathway and its anti-tumour effect human MG-63 osteosarcoma cells. The in silico study on benzylisoquinoline alkaloids was carried out for analyzing and shortlisting of compounds using a virtual screening, Lipinski’s rule, bioavailability graphical RADAR plot, pharmacokinetics, toxicity, and molecular docking studies. Among the benzylisoquinoline alkaloids, stylopine was selected and subjected to in-vitro studies against human MG-63 osteosarcoma cells. Various experiments such as MTT assay, EtBr/AO staining, mitochondrial membrane potential assessment, transwell migration assay, gene expression analysis by a quantitative real time polymerase chain reaction (qRT-PCR) method, SDS-PAGE followed by immunoblotting were performed to evaluate its anti-tumour effect as compared to standard axitinib. The MTT assay indicates that stylopine inhibits cell proliferation in MG-63 cells. Similarly, as confirmed by the EtBr/Ao staining method, the MMP assay indicates that stylopine induces mitochondrial membrane damage and apoptosis as compared to axitinib. Moreover, stylopine inhibits the VEGF-165 induced MG-63 cell migration by a trans-well migration assay. The immunoblotting and qRT-PCR analysis showed that stylopine inhibits the VEGF-165 induced VEGFR2 expression in MG-63 cells. It is concluded that stylopine has potential to regulate VEGFR2 and can inhibit osteosarcoma cells to offer a new drug candidate for the treatment of bone cancer in future.

Schlagwörter

Stichwörter der Autor:innen

MG-63VEGFR2benzylisoquinoline alkaloidsosteosarcomastylopine

Autor:innen und Institutionen

  • Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India.
  • Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • Department of Foundation, RCSI and UCD Malaysia Campus, George Town, Pulau Pinang, Malaysia.
  • Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, Saudi Arabia.
  • Faculty of Health and Life Sciences, INTI International University, Nilai, Malaysia.

Zitieren

APA

Velayutham, N. K., Thamaraikani, T., Wahab, S., Khalid, M., Ramachawolran, G., Abullais, S. S., Wong, L. S., Sekar, M., Gan, S. H., Ebenezer, A. J., Ravikumar, M., Subramaniyan, V., Mat Rani, N. N. I., Wu, Y. S., & Jeyabalan, S. (2023). Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1150270

Vancouver

Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, et al. Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1150270

BibTeX
@article{Velayutham2023,
  author = {Velayutham, Naveen Kumar and Thamaraikani, Tamilanban and Wahab, Shadma and Khalid, Mohammad and Ramachawolran, Gobinath and Abullais, Shahabe Saquib and Wong, Ling Shing and Sekar, Mahendran and Gan, Siew Hua and Ebenezer, Angel Jemima and Ravikumar, Mrinalini and Subramaniyan, Vetriselvan and Mat Rani, Nur Najihah Izzati and Wu, Yuan Seng and Jeyabalan, Srikanth},
  title = {Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1150270}
}
Kostenlos starten →